Allan Hackshaw

Jan 9, 2025 | nature.com | Dhruva Biswas |Yun-Hsin Liu |Javier Herrero |Yin Chao Wu |David Moore |Takahiro Karasaki | +18 more

AbstractHuman tumors are diverse in their natural history and response to treatment, which in part results from genetic and transcriptomic heterogeneity. In clinical practice, single-site needle biopsies are used to sample this diversity, but cancer biomarkers may be confounded by spatiogenomic heterogeneity within individual tumors.

Dec 5, 2024 | nature.com | Sanjay Popat |James B. Spicer |Allan Hackshaw

AbstractHere we present long-term outcomes of first line afatinib in comorbid patients with suspected or confirmed EGFR mutant NSCLC otherwise considered unsuitable for chemotherapy, and the clinical utility of serial ctDNA monitoring. TIMELY (NCT01415011) was a multicentre, single arm, phase II trial conducted in the UK. Patients aged ≥18 were treated with daily oral afatinib (40 mg) until disease progression or unacceptable toxicity.

Jul 4, 2024 | nature.com | Alexander Frankell |Michelle Dietzen |Maise Al Bakir |Takahiro Karasaki |Sophia Ward |Emma Colliver | +25 more

Correction to: Nature https://doi.org/10.1038/s41586-023-05783-5 Published online 12 April 2023In the version of the article initially published, the symbols for death (x) and censored (>) were swapped in the graphs in Fig. 1. The figure has now been corrected in the HTML and PDF versions of the article.

Apr 1, 2023 | bmjoncology.bmj.com | Allan Hackshaw

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. Drug deliveryMedical oncologyThe majority of the initial seminal cancer treatment trials during the 1970s and later on focused on clinical efficacy and clinician-assessed harms.